Medicare de-fangs new drug pricing model

Medicare’s New Global Drug Pricing Test Begins With Narrow Reach

Provpnadvice.com – The Trump administration has finalized a new Medicare payment initiative intended to bring the cost of certain physician-administered medicines closer to prices paid in other countries. The program, called the Global Benchmark for Efficient Drug Pricing model, or GLOBE, is part of President Trump’s broader effort to place prescription drug affordability at the center of his administration’s healthcare agenda.

Yet the final policy is far more limited than the version first put forward. While it remains mandatory for companies that fall within its scope, the number of affected drugmakers and the expected savings have both fallen sharply.

Under GLOBE, manufacturers may have to provide Medicare rebates when the price of a qualifying drug rises above benchmarks drawn from selected foreign markets. The model focuses on medicines covered under traditional Medicare Part B, which generally includes drugs administered in doctors’ offices, clinics and other outpatient settings rather than prescriptions patients pick up at a pharmacy.

Projected Savings Fall From Billions to Millions

Federal estimates now put savings from the final GLOBE model at $440 million over seven years. That figure is 96 percent below the nearly $12 billion in savings projected for the proposed version during the same time frame.

The smaller estimate reflects a substantially reduced universe of companies and products. The original proposal was expected to involve roughly 40 firms. The finalized approach applies to only three companies.

CMS also expects the program initially to touch less than 1 percent of eligible Medicare Part B drug spending. To be considered for the model, a medicine must represent more than $100 million annually in spending under traditional Part B.

That threshold directs the policy toward high-cost medicines with sizable Medicare expenditures. However, the combination of eligibility requirements and exemptions means many therapies that might otherwise appear to fit the model are not expected to be included at the start.

Exemptions Shape the Final Program

A major exception applies to manufacturers that have reached separate arrangements with the White House involving “most-favored-nation” pricing in Medicaid. Those agreements can remove companies from the new Medicare model.

The exemptions have drawn criticism from outside the administration. Brian Reid, a consultant to the drug industry, argued that the final framework has been designed so narrowly that its practical impact will be limited.

The government has crafted it in such a way that it will touch almost no drugs and deliver almost no savings.

The final design illustrates the challenge of translating an international-reference pricing concept into a Medicare payment model. Drug pricing varies among countries for many reasons, including national purchasing systems, negotiations, coverage rules and market structures. Applying overseas benchmarks to the United States can therefore require detailed decisions about which products qualify, which countries are used for comparison and how rebates are calculated.

For Medicare beneficiaries, the immediate effect may be difficult to see. The model targets a small share of Part B spending, and it is structured as a payment test rather than a broad, across-the-board reduction in drug prices. Still, it represents another attempt to use Medicare’s purchasing role to pressure manufacturers toward lower net costs.

Administration Frames GLOBE as a Pilot

CMS Administrator Mehmet Oz described the initiative as an effort to pair lower costs with continued support for medical progress and patient care.

At CMS, we’re focused on more than promises to make healthcare more affordable — we’re taking action to pilot a new approach to lower costs and strengthen the quality of care while preserving medical innovation.

The reference to a pilot is important. Medicare payment demonstrations can test policies on a limited basis before policymakers decide whether a broader program is justified. The GLOBE model’s narrow initial coverage means its results may be closely watched for evidence about whether international price benchmarks can produce savings without disrupting access to treatment or reducing incentives for innovation.

Part B drug spending has long been a focus of federal policymakers because many treatments in the program are expensive specialty medicines administered by healthcare professionals. Unlike standard retail prescriptions, these drugs are often purchased, stored and provided by physicians or outpatient facilities before reimbursement is sought from Medicare. Payment policy can therefore affect not only manufacturers but also clinical practices and the providers who deliver treatment.

The administration’s final approach appears designed to preserve the central goal of comparing certain U.S. prices with those abroad while limiting the number of companies subject to the model. Supporters of international benchmarking argue that Americans should not pay dramatically more than patients in comparable countries for the same medicines. Critics often warn that broad price controls could affect drug development, manufacturer decisions and the availability of treatments.

For now, the final estimates suggest GLOBE will be a modest component of the administration’s drug-pricing strategy rather than a major source of Medicare savings. Its $440 million projected reduction over seven years is meaningful in absolute terms, but small when compared with overall federal healthcare spending and dramatically lower than the savings forecast for the earlier proposal.

The next question will be whether the limited model produces results that lead CMS to expand, revise or replace it. Its early scope—three companies and a fraction of eligible Part B spending—ensures that the program’s real-world effect will depend heavily on implementation, manufacturer participation and the details of the foreign-price comparisons used to determine potential rebates.